FDA approves Imbruvica (ibrutinib) for mantle cell lymphoma (MCL)

Washington (DC) – November 13, 2013 – The U. S. Food and Drug Administration granted accelerated approval to Imbruvica (ibrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Source: Original Article